Denteric is developing precision immunotherapies targeting chronic infections caused by _Porphyromonas gingivalis_ (Pg), with an initial focus on severe periodontal disease. Their first product neutralizes circulating virulence factors produced by Pg, addressing the health complications associated with these infections.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic infections caused by _Porphyromonas gingivalis_ (Pg) can lead to severe periodontal disease and other health complications. Current treatments do not effectively neutralize the virulence factors (toxins) produced by _Pg_ that circulate in the blood.
Solution
Denteric is developing precision immunotherapies specifically targeting chronic _Porphyromonas gingivalis_ (Pg) infections. Their lead product is designed to neutralize circulating virulence factors produced by _Pg_, addressing the underlying cause of associated health complications, with an initial focus on severe periodontal disease. This approach aims to provide a more targeted and effective treatment option compared to existing methods.
Target Audience
The primary target audience includes patients suffering from severe periodontal disease and clinicians treating _Porphyromonas gingivalis_ (_Pg_) related diseases.
Features
- Immunotherapy targeting _Porphyromonas gingivalis_ (_Pg_)
- Neutralizes circulating virulence factors (toxins) produced by _Pg_
- Focus on treating severe periodontal disease